DNTH Dianthus Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DNTH

Price (delayed)

$25.8

Market cap

$757.15M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.45

Enterprise value

$625.41M

magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused ...

Highlights
Dianthus Therapeutics's quick ratio has surged by 83% YoY and by 24% QoQ
The EPS has soared by 74% YoY and by 65% QoQ
The gross profit has dropped by 56% year-on-year but it is up by 35% since the previous quarter
The revenue has plunged by 56% YoY but it has grown by 35% from the previous quarter
DNTH's equity is down by 5% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.magentatx.com/
Peers: OMER OMGA

Key stats

What are the main financial stats of DNTH
Market
Shares outstanding
29.35M
Market cap
$757.15M
Enterprise value
$625.41M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.26
Price to sales (P/S)
47.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
221.3
Earnings
Revenue
$2.83M
EBIT
-$43.56M
EBITDA
-$43.2M
Free cash flow
-$36.97M
Per share
EPS
-$8.45
Free cash flow per share
-$7.17
Book value per share
$11.4
Revenue per share
$0.55
TBVPS
$34.81
Balance sheet
Total assets
$179.41M
Total liabilities
$10.54M
Debt
$585,000
Equity
$168.87M
Working capital
$167.82M
Liquidity
Debt to equity
0
Current ratio
18.42
Quick ratio
18.09
Net debt/EBITDA
3.05
Margins
EBITDA margin
-1,528.7%
Gross margin
100%
Net margin
-1,541.2%
Operating margin
-1,704.7%
Efficiency
Return on assets
-32.6%
Return on equity
-34.9%
Return on invested capital
-174.3%
Return on capital employed
-25.7%
Return on sales
-1,541.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DNTH stock price

How has the Dianthus Therapeutics stock price performed over time
Intraday
7.46%
1 week
20%
1 month
-1.64%
1 year
3,809.09%
YTD
148.08%
QTD
-14%

Financial performance

How have Dianthus Therapeutics's revenue and profit performed over time
Revenue
$2.83M
Gross profit
$2.83M
Operating income
-$48.17M
Net income
-$43.56M
Gross margin
100%
Net margin
-1,541.2%
The operating income has plunged by 62% YoY but it has grown by 27% from the previous quarter
The gross profit has dropped by 56% year-on-year but it is up by 35% since the previous quarter
The revenue has plunged by 56% YoY but it has grown by 35% from the previous quarter
Dianthus Therapeutics's net income has shrunk by 53% YoY but it has increased by 24% QoQ

Growth

What is Dianthus Therapeutics's growth rate over time

Valuation

What is Dianthus Therapeutics stock price valuation
P/E
N/A
P/B
2.26
P/S
47.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
221.3
The EPS has soared by 74% YoY and by 65% QoQ
The stock's price to book (P/B) is 26% more than its 5-year quarterly average of 1.8
DNTH's equity is down by 5% QoQ
DNTH's P/S is 123% above its last 4 quarters average of 21.1
The revenue has plunged by 56% YoY but it has grown by 35% from the previous quarter

Efficiency

How efficient is Dianthus Therapeutics business performance
DNTH's return on assets has dropped by 76% year-on-year but it is up by 38% since the previous quarter
The ROE has soared by 56% QoQ but it has decreased by 12% YoY
The ROS rose by 44% QoQ
DNTH's return on invested capital is up by 7% since the previous quarter

Dividends

What is DNTH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DNTH.

Financial health

How did Dianthus Therapeutics financials performed over time
DNTH's total assets has soared by 116% YoY but it is down by 7% QoQ
The current ratio has soared by 85% YoY and by 26% from the previous quarter
DNTH's debt is 100% smaller than its equity
The debt to equity has soared by 100% YoY
DNTH's debt is down by 26% year-on-year and by 13% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.